Skip to main content
Premium Trial:

Request an Annual Quote

Sequenta Secures Rights to iRepertoire IP for Immune Cell Sequencing

NEW YORK (GenomeWeb News) – Sequenta has gained the exclusive rights to iRepertoire's IP related to methods of immune cell sequencing for minimal residual disease testing, the two companies said today.

iRepertoire's IP complements Sequenta's existing MRD patents and strengthens its ability to provide new products and new features, they said. Sequenta in February began offering its ClonoSight test through its CLIA laboratory. The test is based on the South San Francisco, Calif.-based company's LymphoSight technology, which sequences unique DNA signatures present in immune cells, allowing researchers to track malignant sub-populations at levels as low as one cell per million white blood cells.

Last month, Sequenta said it raised $20 million in a Series C financing round.

iRepertoire, headquartered in Huntsville, Ala., markets tools for immune profiling. Through its R10k program it also discovers and develops immune repertoire signatures.

"This deal underscores the value of immune cell profiling and of our platform and will enable us to move our business forward in other areas," iRepertoire CEO Jian Han said in a statement.

Financial and other terms of the deal were not disclosed.